Payment overview · 2025
General Payments
$850.08
39 reported records · 13 companies
Healthcare provider profile · identity verified
Aaron Jay Mitchell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MARION, AR · NPI 1275852188
Verified facts
What the public records show
CMS Open Payments records show Aaron Jay Mitchell, M.D. received $850.08 in general payments during 2025 across 39 reported records.
Abbott Laboratories accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $226.06 | 26.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.42 | 19.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.07 | 16.8% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.96 | 16.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.62 | 3.4% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $24.91 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.96 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.68 | 2.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.34 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.44 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.02 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.02 | 1.6% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $13.58 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $850.08 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $226.06 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $166.42 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $112.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.24 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.24 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.95 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.62 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.20 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.83 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.63 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $9.10 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 359 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
359 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
222 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1362 | 415 |
| Amlodipine Besylate | Amlodipine Besylate | 1081 | 328 |
| Losartan Potassium | Losartan Potassium | 572 | 180 |
| Omeprazole | Omeprazole | 511 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 451 | 158 |
| Lisinopril | Lisinopril | 447 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 124 |
| Furosemide | Furosemide | 379 | 141 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 369 | 95 |
| Ozempic | Semaglutide | 359 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 354 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 337 | 98 |
| Gabapentin | Gabapentin | 311 | 116 |
| Metformin Hcl Er | Metformin Hcl | 259 | 75 |
| Metformin Hcl | Metformin Hcl | 242 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 242 | 81 |
| Hydralazine Hcl | Hydralazine Hcl | 234 | 80 |
| Eliquis | Apixaban | 222 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 77 |
| Jardiance | Empagliflozin | 218 | 61 |
| Potassium Chloride | Potassium Chloride | 207 | 70 |
| Simvastatin | Simvastatin | 205 | 68 |
| Sertraline Hcl | Sertraline Hcl | 199 | 65 |
| Meloxicam | Meloxicam | 196 | 76 |
| Allopurinol | Allopurinol | 195 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 76 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 181 | 58 |
| Carvedilol | Carvedilol | 179 | 62 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 55 |
| Spironolactone | Spironolactone | 171 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 74 |
| Atenolol | Atenolol | 145 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 44 |
| Famotidine | Famotidine | 142 | 48 |
| Finasteride | Finasteride | 139 | 41 |
| Trazodone Hcl | Trazodone Hcl | 130 | 41 |
| Alendronate Sodium | Alendronate Sodium | 124 | 42 |
| Ezetimibe | Ezetimibe | 123 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 122 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 42 |
| Tresiba Flextouch U-200 | Insulin Degludec | 109 | 36 |
| Montelukast Sodium | Montelukast Sodium | 108 | 36 |
| Glimepiride | Glimepiride | 106 | 36 |
| Tramadol Hcl | Tramadol Hcl | 102 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 30 |
| Alprazolam | Alprazolam | 91 | 31 |
| Farxiga | Dapagliflozin Propanediol | 91 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 85 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 85 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 81 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 21 |
| Donepezil Hcl | Donepezil Hcl | 70 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 29 |
| Linzess | Linaclotide | 63 | 19 |
| Bupropion Xl | Bupropion Hcl | 60 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 24 |
| Chlorthalidone | Chlorthalidone | 57 | 17 |
| Lorazepam | Lorazepam | 57 | 25 |
| Pregabalin | Pregabalin | 57 | 24 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 54 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 52 | 15 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 50 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 24 |
| Celecoxib | Celecoxib | 49 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Dutasteride | Dutasteride | 47 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 17 |
| Methylprednisolone | Methylprednisolone | 46 | 45 |
| Primidone | Primidone | 45 | 11 |
| Benazepril Hcl | Benazepril Hcl | 44 | 12 |
| Naproxen | Naproxen | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 14 |
| Memantine Hcl | Memantine Hcl | 41 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 15 |
| Diazepam | Diazepam | 39 | 17 |
| Nifedipine Er | Nifedipine | 39 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 11 |
| Xarelto | Rivaroxaban | 38 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 16 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | 12 |
| Bumetanide | Bumetanide | 33 | 14 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 29 |
| Kerendia | Finerenone | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | 11 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Clonazepam | Clonazepam | 31 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 15 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 15 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | 12 |
| Ondansetron Odt | Ondansetron | 28 | 18 |
| Prednisone | Prednisone | 28 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Ramipril | Ramipril | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Topiramate | Topiramate | 25 | 13 |
| Valsartan | Valsartan | 25 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 13 |
| Baclofen | Baclofen | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | 14 |
| Methimazole | Methimazole | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | 15 |
| Azithromycin | Azithromycin | 15 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $850.08 · 39 records | Abbott Laboratories | AIRSUPRA, BREZTRI, CREON, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, IBSRELA, Kerendia, LINZESS, NURTEC ODT, OTEZLA, Omnipod, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error